Call us 24/7

Clinical trials

Search our clinical trials

Cancer Treatment Centers of America® (CTCA) is committed to providing new and innovative treatments for our cancer patients whenever possible. This includes enrolling qualified patients in carefully selected clinical trials for cancer. Clinical trials are a key testing ground for determining the effectiveness and safety of new treatments and drugs for cancer and other diseases. Our doctors may recommend that cancer patients enroll in cancer clinical trials if they meet specific criteria. Cancer trials may offer patients access to treatment options that would otherwise be unavailable to them. Talk to your doctor about whether a cancer trial is a good option for you and ask about the risks and various requirements involved. Use the tool below to find a CTCA® clinical trial for your cancer type.

Filters

46 Clinical Trials

The main objective of the trial is to assess the anti-tumor activity of xentuzumab in combination with everolimus and exemestane over everolimus and exemestane in post-menopausal patients with HR+/ HER2- advanced or metastatic breast cancer and non-visceral disease.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is a randomized (1:1), double-blind, placebo-controlled, Phase 3 study designed to compare the efficacy and safety of tislelizumab or placebo plus chemotherapy as first-line therapy for locally advanced, unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

The study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trastuzumab in combination with SOC chemotherapy in participants with HER2-positive gastric cancer. The primary hypotheses of the study are that pembrolizumab plus trastuzumab in combination with chemotherapy is superior to trastuzumab plus chemotherapy in terms of 1) progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR), and 2) overall survival (OS).

This is an open-label, nonrandomized, phase 1 dose escalation, dose expansion, and phase 2 study targeting tumors with FGF/FGFR aberrations. The purpose of the study is to evaluate the safety, tolerability, PK, pharmacodynamic, and anti-tumor activity of TAS-120 in patients with advanced solid tumors with and without FGF/FGFR-related abnormalities.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The study will be conducted in two parts:

The purpose of part 1 is to assess the safety and tolerability of irinotecan liposome injection monotherapy and to determine the irinotecan liposome injection monotherapy dose for part 2 of the study.

The purpose of part 2 is to assess irinotecan liposome injection versus intravenous topotecan in patients with small cell lung cancer who have progressed on or after platinum-based first-line therapy.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy before surgery (neoadjuvant phase), followed by pembrolizumab alone after surgery (adjuvant phase) in participants with resectable stage IIB or IIIA non-small cell lung cancer (NSCLC).

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This National Cancer Institute (NCI)-NRG ALK Protocol phase II trial studies how well a combination of different biomarker/ALK inhibitors work in treating patients with stage IV ALK positive non-squamous non-small cell lung cancer.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This phase II/III trial studies how well chemotherapy and radiation therapy (chemoradiation) with or without atezolizumab works in treating patients with limited stage small cell lung cancer.